Federal Judge Orders Hegseth to Explain Military Testosterone Policy Discrepancy

Summary

A federal judge this week ordered Pete Hegseth to explain a contradiction at the heart of the Pentagon's new testosterone screening program: the Defense Department plans to test male service members aged 30 and older for low testosterone and offer hormone treatment as needed, while simultaneously barring transgender troops from receiving the same hormone. Hegseth announced the policy earlier this month, framing it as a readiness issue, arguing that male service members should have the "right testosterone levels" to perform optimally. The judge's order puts the administration in the position of arguing that testosterone is both a military necessity and a disqualifying treatment, depending on who is receiving it. The Veterans Affairs system adds another layer of complication. Medical experts have pointed out that testosterone therapy carries real clinical consequences, including reduced sperm counts in men who take it, and the VA has already faced significant challenges administering the treatment, including gaps in follow-up and continuing care. No stated plan for ongoing clinical management of the new program has been made public. The policy sits at the intersection of two of Hegseth's defining priorities, maximizing combat readiness and eliminating what he calls gender ideology from the military, and a federal court is now forcing him to reconcile them on paper.